Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2018

01-06-2018 | Original Article

Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein

Authors: George E. Duran, Volker Derdau, Dietmar Weitz, Nicolas Philippe, Jörg Blankenstein, Jens Atzrodt, Dorothée Sémiond, Diego A. Gianolio, Sandrine Macé, Branimir I. Sikic

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2018

Login to get access

Abstract

Purpose

The primary aim of this study was to determine cabazitaxel’s affinity for the ABCB1/P-glycoprotein (P-gp) transporter compared to first-generation taxanes.

Methods

We determined the kinetics of drug accumulation and retention using [14C]-labeled taxanes in multidrug-resistant (MDR) cells. In addition, membrane-enriched fractions isolated from doxorubicin-selected MES-SA/Dx5 cells were used to determine sodium orthovanadate-sensitive ATPase stimulation after exposure to taxanes. Custom [3H]-azido-taxane analogues were synthesized for the photoaffinity labeling of P-gp.

Results

The maximum intracellular drug concentration was achieved faster with [14C]-cabazitaxel (5 min) than [14C]-docetaxel (15–30 min). MDR cells accumulated twice as much cabazitaxel than docetaxel, and these levels could be restored to parental levels in the presence of the P-gp inhibitor PSC-833 (valspodar). Efflux in drug-free medium confirmed that MDR cells retained twice as much cabazitaxel than docetaxel. There was a strong association (r2 = 0.91) between the degree of taxane resistance conferred by P-gp expression and the accumulation differences observed with the two taxanes. One cell model expressing low levels of P-gp was not cross-resistant to cabazitaxel while demonstrating modest resistance to docetaxel. Furthermore, there was a 1.9 × reduction in sodium orthovanadate-sensitive ATPase stimulation resulting from treatment with cabazitaxel compared to docetaxel. We calculated a dissociation constant (Kd) value of 1.7 µM for [3H]-azido-docetaxel and ~ 7.5 µM for [3H]-azido-cabazitaxel resulting in a 4.4 × difference in P-gp labeling, and cold docetaxel was a more effective competitor than cabazitaxel.

Conclusion

Our studies confirm that cabazitaxel is more active in ABCB1(+) cell models due to its reduced affinity for P-gp compared to docetaxel.
Appendix
Available only for authorised users
Literature
1.
go back to reference Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JT, Fojo T et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125CrossRefPubMed Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JT, Fojo T et al (1997) Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272:17118–17125CrossRefPubMed
2.
go back to reference Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Cancer 31(2):277–283 Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Cancer 31(2):277–283
3.
go back to reference Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U (2011) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65(1):40–45CrossRefPubMed Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I, Gündüz U (2011) Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65(1):40–45CrossRefPubMed
4.
go back to reference Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X et al (2014) Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer 110:1958–1967CrossRefPubMedPubMedCentral Yang Q, Huang J, Wu Q, Cai Y, Zhu L, Lu X et al (2014) Acquisition of epithelial–mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells. Br J Cancer 110:1958–1967CrossRefPubMedPubMedCentral
5.
go back to reference Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J et al (2015) Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14(1):193–201CrossRefPubMed Duran GE, Wang YC, Francisco EB, Rose JC, Martinez FJ, Coller J et al (2015) Mechanisms of resistance to cabazitaxel. Mol Cancer Ther 14(1):193–201CrossRefPubMed
6.
go back to reference Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2006) BRCA1 downregulation leads to premature inactivation of spndle checkpoint and confers paclitaxel resistance. Cell Cycle 5(9):1001–1007CrossRefPubMed Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F (2006) BRCA1 downregulation leads to premature inactivation of spndle checkpoint and confers paclitaxel resistance. Cell Cycle 5(9):1001–1007CrossRefPubMed
7.
go back to reference Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20(45):6597–6606CrossRefPubMed Lafarge S, Sylvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20(45):6597–6606CrossRefPubMed
8.
go back to reference Mullan PB, Quinn PE, Gilmore PM, McWilliams S, Andrews H, Gervin C et al (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20:6123–6131CrossRefPubMed Mullan PB, Quinn PE, Gilmore PM, McWilliams S, Andrews H, Gervin C et al (2001) BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 20:6123–6131CrossRefPubMed
9.
go back to reference Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GKF et al (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13(24):7413–7420CrossRefPubMed Quinn JE, James CR, Stewart GE, Mulligan JM, White P, Chang GKF et al (2007) BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13(24):7413–7420CrossRefPubMed
10.
go back to reference Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Can Res 63:6221–6228 Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG et al (2003) BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Can Res 63:6221–6228
11.
go back to reference Sung M, Giannakakou P (2013) BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 33(11):1418–1428CrossRef Sung M, Giannakakou P (2013) BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling. Oncogene 33(11):1418–1428CrossRef
12.
go back to reference Srivastava RK, Mi QS, Hardwick JM, Longo DL (1999) Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96(7):3775–3780CrossRefPubMedPubMedCentral Srivastava RK, Mi QS, Hardwick JM, Longo DL (1999) Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 96(7):3775–3780CrossRefPubMedPubMedCentral
13.
go back to reference Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V et al (1994) High levels of p26 BCL2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960–1969PubMed Tang C, Willingham MC, Reed JC, Miyashita T, Ray S, Ponnathpur V et al (1994) High levels of p26 BCL2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. Leukemia 8:1960–1969PubMed
14.
go back to reference Reed JC (1999) Bcl-2 family proteins: relative importance as determinants of chemoresistance in cancer. In: Hickman JA, Dive C (eds) Apoptosis and Cancer Chemotherapy, Humana Press, Totowa, NJ Reed JC (1999) Bcl-2 family proteins: relative importance as determinants of chemoresistance in cancer. In: Hickman JA, Dive C (eds) Apoptosis and Cancer Chemotherapy, Humana Press, Totowa, NJ
15.
go back to reference Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK et al (2006) Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 45(4):365–374CrossRefPubMed Wang YC, Juric D, Francisco B, Yu RX, Duran GE, Chen GK et al (2006) Regional activation of chromosomal arm 7q with and without gene amplification in taxane-selected human ovarian cancer cell lines. Genes Chromosomes Cancer 45(4):365–374CrossRefPubMed
16.
go back to reference Horwitz S, Cohen D, Rao S, Ringel I, Shen H, Yang C (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst 15:55–61 Horwitz S, Cohen D, Rao S, Ringel I, Shen H, Yang C (1993) Taxol: mechanisms of action and resistance. J Natl Cancer Inst 15:55–61
17.
go back to reference Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56:1091–1097PubMed Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI (1996) Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol). Cancer Res 56:1091–1097PubMed
18.
go back to reference Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillardt MR et al (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of MDR1. Int J Cancer 130(8):1787–1797CrossRefPubMed Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillardt MR et al (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of MDR1. Int J Cancer 130(8):1787–1797CrossRefPubMed
19.
go back to reference Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C et al (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19(11):2973–2983CrossRefPubMed Vrignaud P, Sémiond D, Lejeune P, Bouchard H, Calvet L, Combeau C et al (2013) Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin Cancer Res 19(11):2973–2983CrossRefPubMed
20.
go back to reference Sémiond D, Sidhu SS, Bissery MC, Vrignaud P (2013) Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Cheother Pharmacol 72(3):515–528CrossRef Sémiond D, Sidhu SS, Bissery MC, Vrignaud P (2013) Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel. Cancer Cheother Pharmacol 72(3):515–528CrossRef
21.
go back to reference Duran GE, Ford JM, Sikic BI (2000) A paclitaxel-resistant mutant with altered p53-dependent MAP4 expression and drug binding. In: Proceedings of the 91st annual meeting of the American Association for Cancer Research; 1–5 April 2000; San Francisco, CA. AACR, Philadelphia Duran GE, Ford JM, Sikic BI (2000) A paclitaxel-resistant mutant with altered p53-dependent MAP4 expression and drug binding. In: Proceedings of the 91st annual meeting of the American Association for Cancer Research; 1–5 April 2000; San Francisco, CA. AACR, Philadelphia
22.
go back to reference Lacayo NJ, Duran GE, Sikic BI (2003) Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. J Exp Ther Oncol 3:127–135CrossRefPubMed Lacayo NJ, Duran GE, Sikic BI (2003) Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells. J Exp Ther Oncol 3:127–135CrossRefPubMed
23.
go back to reference de Ravel M, Alameh G, Melikian M, Mahiout Z, Emptoz-Bonneton A, Matera E-L et al (2015) Synthesis of new steroidal inhibitors of P‑glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells. J Med Chem 58:1832–1845CrossRefPubMed de Ravel M, Alameh G, Melikian M, Mahiout Z, Emptoz-Bonneton A, Matera E-L et al (2015) Synthesis of new steroidal inhibitors of P‑glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells. J Med Chem 58:1832–1845CrossRefPubMed
24.
go back to reference Ginot L, Jeammesson P, Angiboust J-F, Jardillier J-C, Manfait M (1984) Interactions of adriamycin in sensitive and resistant leukemic cells: a comparative study by microspectrofluorometry. Stud Biophys 104:145–153 Ginot L, Jeammesson P, Angiboust J-F, Jardillier J-C, Manfait M (1984) Interactions of adriamycin in sensitive and resistant leukemic cells: a comparative study by microspectrofluorometry. Stud Biophys 104:145–153
25.
go back to reference Spicakova T, O’Brien MM, Duran GE, Sweet-Cordero A, Sikic BI (2010) Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 9(11):2970–2981CrossRefPubMedPubMedCentral Spicakova T, O’Brien MM, Duran GE, Sweet-Cordero A, Sikic BI (2010) Expression and silencing of the microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther 9(11):2970–2981CrossRefPubMedPubMedCentral
26.
go back to reference Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987–3994PubMed Minotti AM, Barlow SB, Cabral F (1991) Resistance to antimitotic drugs in chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987–3994PubMed
27.
go back to reference Chen CKLN., Duran GE, Cohen D, Sikic BI (2000) Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted Phe335. Mol Pharm 57:769–777CrossRef Chen CKLN., Duran GE, Cohen D, Sikic BI (2000) Loss of cyclosporin and azidopine binding are associated with altered ATPase activity by a mutant P-glycoprotein with deleted Phe335. Mol Pharm 57:769–777CrossRef
28.
go back to reference Orr GA, Rao S, Swindell CS, Kingston DG, Horwitz SB (1998) Photoaffinity labeling approach to map the Taxol-binding site on the microtubule. Methods Enzymol 298:238–252CrossRefPubMed Orr GA, Rao S, Swindell CS, Kingston DG, Horwitz SB (1998) Photoaffinity labeling approach to map the Taxol-binding site on the microtubule. Methods Enzymol 298:238–252CrossRefPubMed
29.
go back to reference Rao S, Orr GA, Chaundhary AG, Kingston DG, Horwtiz SB (1995) Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217–231) of beta-tubulin. J Biol Chem 270(35):20235–20238CrossRefPubMed Rao S, Orr GA, Chaundhary AG, Kingston DG, Horwtiz SB (1995) Characterization of the taxol binding site on the microtubule. 2-(m-Azidobenzoyl)taxol photolabels a peptide (amino acids 217–231) of beta-tubulin. J Biol Chem 270(35):20235–20238CrossRefPubMed
30.
go back to reference Wu Q, Bounaud PY, Kuduk SD, Yang CP, Ojima I, Horwtiz SB et al (1998) Identification of the domains of photoincorporation of the 3′- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. Biochemistry 37(32):11272–11279CrossRefPubMed Wu Q, Bounaud PY, Kuduk SD, Yang CP, Ojima I, Horwtiz SB et al (1998) Identification of the domains of photoincorporation of the 3′- and 7-benzophenone analogues of taxol in the carboxyl-terminal half of murine mdr1b P-glycoprotein. Biochemistry 37(32):11272–11279CrossRefPubMed
31.
go back to reference Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life 53(4–5):269–274CrossRefPubMed Ojima I, Geney R, Ungureanu IM, Li D (2002) Medicinal chemistry and chemical biology of new generation taxane antitumor agents. IUBMB Life 53(4–5):269–274CrossRefPubMed
32.
go back to reference Fletcher J, Haber M, Henderson M, Norris M (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147–156CrossRefPubMed Fletcher J, Haber M, Henderson M, Norris M (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147–156CrossRefPubMed
Metadata
Title
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
Authors
George E. Duran
Volker Derdau
Dietmar Weitz
Nicolas Philippe
Jörg Blankenstein
Jens Atzrodt
Dorothée Sémiond
Diego A. Gianolio
Sandrine Macé
Branimir I. Sikic
Publication date
01-06-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3572-1

Other articles of this Issue 6/2018

Cancer Chemotherapy and Pharmacology 6/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine